[go: up one dir, main page]

PE20081891A1 - Formulaciones de comprimidos que contienen sales de 8-[{1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-diaza-spiro[4.5]decan-2-ona y comprimidos elaborados a partir de estas - Google Patents

Formulaciones de comprimidos que contienen sales de 8-[{1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-diaza-spiro[4.5]decan-2-ona y comprimidos elaborados a partir de estas

Info

Publication number
PE20081891A1
PE20081891A1 PE2008000515A PE2008000515A PE20081891A1 PE 20081891 A1 PE20081891 A1 PE 20081891A1 PE 2008000515 A PE2008000515 A PE 2008000515A PE 2008000515 A PE2008000515 A PE 2008000515A PE 20081891 A1 PE20081891 A1 PE 20081891A1
Authority
PE
Peru
Prior art keywords
phenyl
trifluorometil
etoxy
decan
ona
Prior art date
Application number
PE2008000515A
Other languages
English (en)
Inventor
Zhihui Qiu
Cho Wing-Kee Philip
Na Zhao
Wong Victor Ming-She
Original Assignee
Opko Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39541515&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20081891(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Opko Health Inc filed Critical Opko Health Inc
Publication of PE20081891A1 publication Critical patent/PE20081891A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA EN FORMA DE COMPRIMIDO QUE CONTIENE: A) UNA SAL CLORHIDRATO MONOHIDRATO DE (5S,8S)-8-[{(1R)-1-(3,5-BIS-(TRIFLUOROMETIL)FENIL)-ETOXI}-METIL]-8-FENIL-1,7-DIAZASPIRO[4.5]DECAN-2-ONA, CELULOSA MICROCRISTALINA INTRAGRANULAR, LACTOSA MONOHIDRATO, DESINTEGRANTE INTRAGRANULAR TAL COMO SODIO CROSCARMELOSO, AGLUTINANTE TAL COMO POVIDONA K30, ALMIDON PREGELATINIZADO E HIPROMELOSA; B) CELULOSA MICROCRISTALINA EXTRAGRANULAR, DESINTEGRANTE EXTRAGRANULAR TAL COMO SODIO CROSCARMELOSO, ESTEARATO DE MAGNESIO. SE REFIERE TAMBIEN A UN PROCEDIMIENTO DE PREPARACION DE LA COMPOSICION Y A UN METODO DE TRATAMIENTO DE EMESIS O NAUSEAS
PE2008000515A 2007-03-22 2008-03-19 Formulaciones de comprimidos que contienen sales de 8-[{1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-diaza-spiro[4.5]decan-2-ona y comprimidos elaborados a partir de estas PE20081891A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91950107P 2007-03-22 2007-03-22

Publications (1)

Publication Number Publication Date
PE20081891A1 true PE20081891A1 (es) 2008-12-27

Family

ID=39541515

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000515A PE20081891A1 (es) 2007-03-22 2008-03-19 Formulaciones de comprimidos que contienen sales de 8-[{1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-diaza-spiro[4.5]decan-2-ona y comprimidos elaborados a partir de estas

Country Status (11)

Country Link
US (3) US8361500B2 (es)
EP (1) EP2136793B1 (es)
JP (3) JP5442459B2 (es)
AR (1) AR065802A1 (es)
CA (1) CA2681465C (es)
CL (1) CL2008000819A1 (es)
ES (1) ES2406934T3 (es)
MX (1) MX2009010210A (es)
PE (1) PE20081891A1 (es)
TW (1) TWI350185B (es)
WO (1) WO2008118331A2 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20030762A1 (es) 2001-12-18 2003-09-05 Schering Corp Compuestos heterociclicos como antagonistas nk1
JP5352446B2 (ja) 2006-04-05 2013-11-27 オプコ ヘルス， インコーポレイテッド ８−［｛１−（３，５−ビス−（トリフルオロメチル）フェニル）−エトキシ｝−メチル］−８−フェニル−１，７−ジアザ−スピロ［４．５］デカン−２−オンの塩酸塩およびその調製プロセス
AU2007233389C1 (en) 2006-04-05 2013-07-25 Opko Health, Inc. Pharmaceutical formulations: salts of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same
JP5508003B2 (ja) 2006-06-30 2014-05-28 アイスイティカ ピーティーワイ リミテッド ナノ粒子状の形態における生物学的に活性な化合物の調製のための方法
AR066191A1 (es) 2007-03-22 2009-08-05 Schering Corp Proceso e intermediarios para la sintesis de compuestos 8- [ ( 1- (3,5- bis- ( trifluorometil) fenil) - etoxi ) - metil]- 8 fenil - 1,7- diaza - espiro (4, 5) decan -2 ona
PE20081891A1 (es) * 2007-03-22 2008-12-27 Opko Health Inc Formulaciones de comprimidos que contienen sales de 8-[{1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-diaza-spiro[4.5]decan-2-ona y comprimidos elaborados a partir de estas
BRPI0908731A2 (pt) 2008-03-17 2017-05-16 Bial - Portela & C A S A formas cristalinas de 5-[3-(2,5-dicloro-4,6-dimetil-1-óxi-piridina-3-il)[1,2,4]oxadiazol-5-il]-3-nitrobenzeno-1,2-diol
HUE026148T2 (en) 2008-09-05 2016-05-30 Opko Health Inc 8 - ({1- [3,5-bis (trifluoromethyl) phenyl] ethoxy} methyl) -8-phenyl-1,7-diaza-spiro [4,5] decane-on-compounds intermediates
CN102448444B (zh) 2009-04-01 2016-05-25 巴尔-波特拉及康邦亚股份有限公司 包括硝基儿茶酚衍生物的药物制剂及其制备方法
WO2010114405A2 (en) * 2009-04-01 2010-10-07 Bial - Portela & Ca., S.A. Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making the same
MA33296B1 (fr) 2009-04-24 2012-05-02 Iceutica Pty Ltd Nouvelle formulation d'indométhacine
EA201171281A1 (ru) * 2009-04-24 2012-05-30 Айсьютика Пти Лтд. Производство инкапсулированных наночастиц в коммерческих масшатабах
NZ595973A (en) 2009-04-24 2014-02-28 Iceutica Pty Ltd Production of encapsulated nanoparticles at high volume fractions
UA110773C2 (uk) * 2009-04-24 2016-02-25 Айсьютіка Пті Лтд Спосіб одержання порошків, що містять нано- і мікрочастинки
PH12015501811A1 (en) * 2009-04-24 2019-03-25 Iceutica Pty Ltd Production of encapsulated nanoparticles at high volume fractions
AU2010239082B2 (en) * 2009-04-24 2014-10-16 Iceutica Pty Ltd A novel formulation of metaxalone
JO3635B1 (ar) * 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
RU2017145628A (ru) * 2009-08-14 2019-02-19 ОПКО Хельс, Инк. Композиции антагонистов нейрокинина-1 для внутривенного введения
GB2475701B (en) * 2009-11-26 2011-10-19 Michael Hilary Burke A process for the preparation of an orally administered anthelmintic unit dose tablet
US20140045900A1 (en) 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
US20130303519A1 (en) 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors
US9452107B2 (en) 2012-04-16 2016-09-27 New Jersey Institute Of Technology Systems and methods for superdisintegrant-based composite particles for dispersion and dissolution of agents
WO2014153509A1 (en) 2013-03-22 2014-09-25 Millennium Pharmaceuticals, Inc. Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
CN106866669A (zh) * 2017-04-19 2017-06-20 成都百特万合医药科技有限公司 一种合成罗拉吡坦中间体的方法
CA3143829A1 (en) * 2019-07-19 2021-01-28 Thomas Brad GOLD Pretomanid compositions
WO2023080910A1 (en) * 2020-11-18 2023-05-11 Fb-Hrs, Llc Compositions containing dofetilide and mexiletine and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0812195T3 (da) 1995-02-28 2003-03-03 Aventis Pharma Inc Farmaceutisk sammensætning til piperidinoalkanolforbindelser
SA99191255B1 (ar) * 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
US6499984B1 (en) 2000-05-22 2002-12-31 Warner-Lambert Company Continuous production of pharmaceutical granulation
WO2002024166A1 (fr) * 2000-09-22 2002-03-28 Sumitomo Pharmaceuticals Company, Limited Preparations orales dotees de bonnes caracteristiques de desagregation
PE20030762A1 (es) * 2001-12-18 2003-09-05 Schering Corp Compuestos heterociclicos como antagonistas nk1
ATE413163T1 (de) * 2002-09-17 2008-11-15 Wyeth Corp Granulierte formulierung des rapamycinesters ccl- 779
AU2004278158B2 (en) 2003-10-03 2009-08-13 Pfizer Inc. Imidazopyridine substituted tropane derivatives with CCR5 receptor antagonist activity for the treatment of HIV and inflammation
WO2005063243A1 (en) 2003-12-22 2005-07-14 Schering Corporation Pharmaceutical compositions
JP2007532511A (ja) * 2004-04-09 2007-11-15 スミスクライン ビーチャム コーポレーション 低用量医薬品
US7354922B2 (en) 2004-12-14 2008-04-08 Schering Corporation Bridged ring NK1 antagonists
AU2007233389C1 (en) * 2006-04-05 2013-07-25 Opko Health, Inc. Pharmaceutical formulations: salts of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same
JP5352446B2 (ja) 2006-04-05 2013-11-27 オプコ ヘルス， インコーポレイテッド ８−［｛１−（３，５−ビス−（トリフルオロメチル）フェニル）−エトキシ｝−メチル］−８−フェニル−１，７−ジアザ−スピロ［４．５］デカン−２−オンの塩酸塩およびその調製プロセス
PE20081891A1 (es) 2007-03-22 2008-12-27 Opko Health Inc Formulaciones de comprimidos que contienen sales de 8-[{1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-diaza-spiro[4.5]decan-2-ona y comprimidos elaborados a partir de estas

Also Published As

Publication number Publication date
MX2009010210A (es) 2009-10-19
US8361500B2 (en) 2013-01-29
US20130122088A1 (en) 2013-05-16
JP2015108023A (ja) 2015-06-11
JP6041919B2 (ja) 2016-12-14
JP2010522173A (ja) 2010-07-01
JP5442459B2 (ja) 2014-03-12
US20100104637A1 (en) 2010-04-29
US20150283121A1 (en) 2015-10-08
EP2136793B1 (en) 2013-02-20
EP2136793A2 (en) 2009-12-30
TW200902087A (en) 2009-01-16
CA2681465C (en) 2015-12-15
CA2681465A1 (en) 2008-10-02
JP5763134B2 (ja) 2015-08-12
AR065802A1 (es) 2009-07-01
TWI350185B (en) 2011-10-11
ES2406934T3 (es) 2013-06-10
JP2013216694A (ja) 2013-10-24
CL2008000819A1 (es) 2008-09-26
WO2008118331A2 (en) 2008-10-02
WO2008118331A3 (en) 2009-04-23

Similar Documents

Publication Publication Date Title
PE20081891A1 (es) Formulaciones de comprimidos que contienen sales de 8-[{1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-diaza-spiro[4.5]decan-2-ona y comprimidos elaborados a partir de estas
RU2465263C2 (ru) Фармацевтическая комбинация, включающая 3-(3-диметиламино-1-этил-2-метилпропил)фенол и нестероидный противовоспалительный препарат
PE20120254A1 (es) Formulaciones farmaceuticas de sales de 8-[1-(3,5-bis-(trifluorometil)fenil)-etoximetil]-8-fenil-1,7-diaza-espiro[4,5]decan-2-ona
TN2009000317A1 (en) Solid preparation comprising alogliptin and pioglitazone
JP2006298933A5 (es)
AR065096A1 (es) Preparacion solida
TN2009000093A1 (en) Pharmaceutical compositions comprising nilotinib or its salt
AR065698A1 (es) Preparacion solida
RU2011127989A (ru) Таблетки на основе улипристала ацетата
ECSP077999A (es) Formulaciones de una sal de bupropion de liberación modificada
ME02150B (me) Derivati piperidinona kao inhibitori mdm2 za lečenje kancera
CL2008001103A1 (es) Compuestos derivados de [1,2,3]triazolo[4,5-b]piridin-corboxamidas y [1,2,3]triazolo[4,5-d]pirimidin-carboxamidas, inhibidores de megl y faah; procedimiento de preparacion; composicion farmaceutica; y su uso en el tratamiento de dolores agudos o cronicos, vertigos, vomitos, nauseas, sindrome metabolico, dislipidemia, entre otros.
CL2012000626A1 (es) Composición farmacéutica oral de liberación sostenida, que comprende dentro de una forma de dosificación única, (i) una matriz hidrofílica, (ii) una cantidad terapéuticamente eficaz de un compuesto no opioide que contiene amina, (iii) una sal de un fármaco aine, y (iv) opcionalmente un surfactante aniónico.
UY32062A (es) Inhibidores de beta-secretasa
MA30725B1 (fr) Administration d'inhibiteurs de la dipeptidyl peptidase
CL2009000228A1 (es) Compuestos derivados de 7,8-dihidropirido[4,3-d]pirimidin con un sustituyente oximico, inhibidores de hsp90; y composicion farmaceutica que comprene a dichos compuestos.
AR063096A1 (es) Pirazolopirimidinas como inhibidores de quinasa dependientes de ciclina
MX2009012619A (es) Formulacion farmaceutica estable para un inhibidor de dpp-iv.
MX2010009395A (es) Agonistas de receptores muscarinicos, composiciones, metodos de tratamiento de los mismos, y procesos para preparacion de los mismos.
NO20073551L (no) Nikotinacetylkolinreseptorligander
WO2010098600A3 (en) Substituted azole derivatives, pharmaceutical composition containing the derivatives, and method for treating parkinson's disease using the same
JP2012167125A5 (es)
BRPI0507897A (pt) formulação de droga sólida
AR058904A1 (es) Proceso mejorado para la preparacion de un derivado de 5h-pirrolo[3,4-b] pirazina opticamente activo
ECSP077263A (es)

Legal Events

Date Code Title Description
FG Grant, registration